US Pharma MarketingFDA advisory panels are back, with new meetings for Replimune, Capricor
FDA officials say they’ll place renewed emphasis on advisory meetings for contested product applications. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the…
Under new leadership, FDA officials have said they’ll place renewed emphasis on advisory meetings for contested product applications.
Two new announcements suggest they’re making good on that.
Replimune and
Source: Endpoints News